What Nobel pharma does

Nobel Pharmaceuticals is a Turkish pharmaceutical manufacturer founded in 1964 with 100% domestic capital, operating as part of Ulkar Holding. The company produces generic pharmaceutical products across a broad therapeutic range (cardiovascular, diabetes, neurological, psychiatric, antibacterial, respiratory, gastrointestinal, pain, and anti-inflammatory) in solid, liquid, semi-solid, cephalosporin, parenteral, and dry powder inhaler dosage forms, plus active pharmaceutical ingredients (APIs) at its wholly-owned Ulkar Kimya subsidiary. It operates five manufacturing facilities (Düzce and Çerkezköy in Turkey, Almaty in Kazakhstan via Nobel AFF, Tashkent in Uzbekistan via Nobel Pharmsanoat) and four R&D centers, including the MARTEK biotechnology R&D center at Tübitak Marmara Teknokent, which targets biosimilar and original biological drug development under WHO/EMA/FDA standards.

The company employs approximately 3,000 people, including 65 scientists at the Düzce R&D center. Its business model is B2B sales of pharmaceutical products through its own representative offices in 20 countries (Germany, Albania, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Georgia, Switzerland, Montenegro, Kazakhstan, Kyrgyzstan, Kosovo, Macedonia, Mongolia, Moldova, Uzbekistan, Russia, Serbia, Turkmenistan, and Ukraine), with exports to approximately 50 countries. Revenue streams include pharmaceutical product sales, API exports, and contract manufacturing for international companies at GMP-certified facilities. Notable brands include Tylol Hot, recognized under the same name in 25 countries, and the peer-reviewed medical publication Nobel Medicus.

Nobel's strategic posture is anchored in three pillars: (1) deepening geographic reach via its owned distribution model, exemplified by the 2018 founding of Nobel Pharma Schweiz AG; (2) scaling generics and API production across multi-country manufacturing; and (3) pivoting toward biotechnology, supported by $10M in TÜBİTAK funding for the BIOSIM-1 project and a $25M IFC investment credit. Key certifications include EU-GMP (2009), first Turkish GMP in Kazakhstan (2011), TURQUALITY brand program inclusion (2014), and recognition as a "well-known brand" by the Turkish Patent Institute (2009). The company is the export leader in Turkish pharmaceuticals and the only Turkish pharma without a foreign trade deficit.

Name

Nobel pharma

Legal name

Nobel Pharmaceuticals San. Ve Tic. A.Ş.

Website

https://nobelpharma.bg

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

11–50 employees

Short description

Nobel Pharmaceuticals is a Turkish generic pharmaceutical manufacturer founded in 1964, operating under Ulkar Holding. The company produces drugs, APIs, and biosimilars across five manufacturing facilities in Turkey, Kazakhstan, and Uzbekistan, selling through own offices in 20 countries and exporting to roughly 50.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Biotechnology drugs
• Contract manufacturing

Headquarters

HQ city

Sofia

HQ country

Bulgaria

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: Nobel Pharmaceuticals manufactures and sells pharmaceutical products globally through its own representative offices in 20 countries and exports to nearly 50 countries. Products are manufactured according to international standards.
2. Active Pharmaceutical Ingredient (API) Exports: Export of drug substances and active pharmaceutical ingredients to nearly 50 countries, including exports to Europe, Russia, CIS, Asia, South and North America.
3. Contract Manufacturing: Nobel conducts contract manufacturing for various local and international companies at its GMP-certified facilities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Nobel Pharmaceuticals manufactures and sells generic pharmaceutical products, active pharmaceutical ingredients (APIs), and biotechnological drugs across multiple dosage forms (solid, liquid, semi-solid, sterile, parenteral, dry powder inhalers). The company operates five manufacturing facilities in Turkey, Kazakhstan, and Uzbekistan, conducts sales through its own representative offices in 20 countries, and exports to approximately 50 countries, serving therapeutic areas including cardiovascular, diabetes, neurological, psychiatric, antibacterial, inflammatory, pain, respiratory, and gastrointestinal conditions.

Product overview

Nobel Pharmaceuticals is a Turkish pharmaceutical company founded in 1964 with 100% domestic capital, operating as part of Ulkar Holding. The company operates a comprehensive manufacturing and R&D infrastructure consisting of five production facilities (three in Turkey, one in Kazakhstan, and one in Uzbekistan) and four specialized R&D centers. Their manufacturing capabilities span solid, liquid, semi-solid, and sterile pharmaceutical forms, as well as active pharmaceutical ingredients. The company exports pharmaceutical products to approximately 50 countries and conducts promotional and sales activities through its own organizations in 20 countries. Key brands include Tylol Hot (a leading flu/cold medication), and the product portfolio covers therapeutic areas including cardiovascular, respiratory, neurological, gastrointestinal, anti-infective, and urological conditions. The company also maintains a strong focus on biotechnology, operating a state-of-the-art biotechnological manufacturing facility with MARTEK. Nobel also publishes Nobel Medicus, a peer-reviewed medical journal.

Differentiator

Problem solved

Functional benefit

Brands

• Nobel Medicus: Peer-reviewed, unbiased scientific medical publication supported by Nobel Pharmaceuticals, celebrating 12 years of publishing
• Tylol Hot

Products and services

• Nobel Pharmaceuticals Product Portfolio Diverse portfolio of generic pharmaceutical products covering therapeutic areas including cardiovascular, respiratory, neurological, gastrointestinal, musculoskeletal, anti-infective, endocrine, and urological conditions. Products exported to approximately 50 countries worldwide and sold to healthcare providers and pharmacies.
• Düzce Manufacturing Facility Primary manufacturing facility in Düzce, Turkey covering approximately 40,000 square meters producing solid, liquid, semi-solid, and sterile pharmaceutical forms. Operates with high-speed production and packaging machines implementing Industry 4.0 technologies. Holds ISO 9001, ISO 14001, and OHSAS 18001 certifications.
• Ulkar Kimya API Manufacturing Active pharmaceutical ingredient (API) manufacturing facility in Çerkezköy, Tekirdağ, Turkey. Specialized in production of active pharmaceutical substances and protected micropellet forms across approximately 64,000 square meters. EU-GMP certified since 2009.
• Nobel AFF Manufacturing Manufacturing facility in Almaty, Kazakhstan producing solid, liquid, suspension, semi-solid, and gel pharmaceutical forms. Annual capacity of 750 million tablets, 250 million capsules, 20 million bottles of syrup-suspension, and 10 million tubes of cream-gel. Portfolio includes approximately 250 products covering 83 molecules. First Turkish pharmaceutical manufacturer to receive GMP certificate in Kazakhstan (2011).
• Nobel Pharmsanoat Manufacturing Manufacturing facility in Tashkent, Uzbekistan producing tablets, film-coated tablets, capsules, powder, suspension, drops, spray, nasal spray, and penicillin forms. Annual production capacity of 10 million boxes, with 110 products including 60 molecules. Holds ISO 9001:2008, ISO 22000:2005 (HACCP), and GMP certifications. Collaborates with the Institute of Phytotherapy for locally-sourced herbal medicines.
• Biotechnological Drug Manufacturing (MARTEK/Gebze Facility) Biotechnological drug manufacturing facility with 2x1000L bioreactor capacity, conducting first state-funded biotechnology project in Turkey, starting with cell design and including advanced bioengineering applications. Develops biosimilar and original biological drug products following WHO, EMA, and FDA standards.
• Contract Manufacturing Services Contract manufacturing services for various local and international pharmaceutical companies at GMP-certified facilities, leveraging multiple dosage form capabilities including solid, liquid, semi-solid, sterile, cephalosporin, parenteral, and dry powder inhaler forms.

Quantifiable outcome

• 95% of product portfolio and all dosage forms approved in 39 countries result from in-house R&D
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Bilkent UniversitycoreStrategic or Co-development PartnerJoint development partnership for biotechnological drug development. Part of collaboration that produced Turkey's first biotechnological original molecule development project.
• Tübitak Marmara Teknokent (MARTEK)coreStrategic or Co-development PartnerR&D center for biotechnology located at MARTEK technology park, compliant with GMP/GLP international standards, developing innovative and high-quality products.
• Odgers BerndtsonminorOthersPartnership for CEOx1Day program, enabling new generation managers to gain experience through mentorship.
• Turkish National Olympics Committee (TMOK)minorGTM or Marketing PartnerSupport for Fair Play Universities Caravan initiative visiting universities across Turkey to promote fair play principles and sports values.
• IKSV (Istanbul Foundation for Culture and Arts)minorGTM or Marketing PartnerSupport for IKSV festivals with approach 'Art is worth it', aligned with company's mission for improving quality of life.
• TEGV (Foundation for Volunteer Education in Turkey)minorStrategic or Co-development PartnerVoluntary trainer program for 'Have Fun, Learn, Hygiene' educational program. Nobel received International CSR Award 2016 from JCI for this program.
• Red CrescentminorOthersBlood donation and stem cell donation campaign conducted for 3 years, with Nobel employees volunteering.
• Junior Chamber International (JCI)minorGTM or Marketing PartnerInternational organization with 169,000 members in 114 countries. Nobel Pharmaceuticals received International CSR Award 2016 from JCI for voluntary training program.
• Institute of Phytotherapy, Academy of Sciences of UzbekistanminorStrategic or Co-development PartnerClose collaboration for production of herbal-based medicinal products. Currently 3 out of 5 products with local active substances are exported.
• Leading Turkish Universities and InstitutescoreStrategic or Co-development PartnerJoint projects with leading institutions and universities in Turkey to develop the biotechnology ecosystem and position Turkey globally in this field.

Scale indicators13 records

Recent moves17 records

Expansion highlights6 records

Direct peers

• Krka: Slovenian generic pharmaceutical manufacturer with vertically integrated API production and strong presence in Central/Eastern Europe and CIS. Closely comparable to Nobel in geographic mix, generic focus, and integrated API-plus-finished-dose model.
• Aurobindo Pharma: Indian vertically integrated generic and API manufacturer with global reach. Comparable to Nobel on generic finished-dose plus API model, though at much larger scale and broader geographic exposure including regulated markets.
• Dr. Reddy's Laboratories: Indian multinational with integrated API and generic finished-dose operations plus a growing biosimilars business. Comparable to Nobel on the generic-plus-API-plus-biosimilar trajectory, though with a different geographic anchor.
• Abdi İbrahim: Largest Turkish pharmaceutical company and Nobel's closest domestic competitor. Operates generic and branded pharmaceutical manufacturing with international distribution, comparable in product breadth, geography (CIS, MENA), and Turkish export-led growth profile.
• Hikma Pharmaceuticals: Jordan-headquartered multinational with strong MENA and emerging markets generic presence and growing injectables/biosimilars. Comparable to Nobel on emerging-market distribution emphasis and generic-portfolio approach.
• Stada Arzneimittel: European-focused generic and specialty pharma company with strong CIS and Eastern European presence. Highly comparable to Nobel's regional distribution strategy and generic portfolio, especially in Balkan and CIS markets.
• Polpharma: Poland's largest pharmaceutical manufacturer with broad generic portfolio and API manufacturing. Comparable to Nobel on generics, API integration, and Eastern European/CIS distribution, including Turkish market adjacency.
• Gedeon Richter: Hungarian pharmaceutical company with strong CIS and Eastern European footprint, generic and biosimilar exposure. Comparable to Nobel on regional distribution strength and generic/biosimilar pipeline, with deeper biosimilar commercialization.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with deep API capabilities and a growing biosimilars portfolio. Comparable in business model (generic-plus-API), but with substantially greater scale and a developed-market footprint Nobel lacks.
• Sandoz (Novartis): Global leader in generic pharmaceuticals and biosimilars with integrated API manufacturing. Directly comparable to Nobel on small-molecule generic strategy and increasingly on biosimilars, though at much larger scale and broader geographic reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/NOBEL-Pharma-Bulgaria-342082183104003
• LinkedInlinkedin.com/company/nobel-pharma

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nobel pharma